AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16960528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RAB) 20 mg x d(‐1)
Number of subjects: 24
Study 16960528 — intervention group
Group type: COMPARATOR
Intervention: Sham esophageal infusion (NG tube placed in the distal esophagus, no fluid)
Number of subjects: 24
Study 15240411 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 15240411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study 15240411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15240411 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop test performance
Number of subjects: 0
Study 10676793 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected refractive error
Number of subjects: 5147
Study 10676793 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy
Number of subjects: 5147
Study 10676793 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 5147
Study 10676793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract
Number of subjects: 5147
Study 10676793 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related macular degeneration
Number of subjects: 5147
Study 9678107 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic COC containing 30 micrograms ethinylestradiol and 75 micrograms gestodene
Number of subjects: 44
Study 9678107 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic COC containing 30/40/30 ethinylestradiol and 50/70/100 micrograms gestodene
Number of subjects: 44
Study 8471132 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin (DBQ), an inhibitor of monoamine oxidase
Number of subjects: 0
Study 8471132 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 3520794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily
Number of subjects: 54
Study 3520794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg daily
Number of subjects: 54
Study 3520794 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg single-dose maintenance treatment
Number of subjects: 54
Study 3520794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29503145 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks
Number of subjects: 53
Study 29503145 — intervention group
Group type: COMPARATOR
Intervention: Statin dose reduction by 50% from weeks 6-12 after 6 weeks of standard therapy
Number of subjects: 53
Study 26416996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up
Number of subjects: 964
Study 26416996 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up (Control)
Number of subjects: 964
Study 25352050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina massage therapy (20 minutes, 4-step treatment protocol, 20 sessions over 4 weeks)
Number of subjects: 150
Study 25352050 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics (specific daily dose of ibuprofen)
Number of subjects: 150
Study 25352050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina massage therapy
Number of subjects: 150
Study 22343553 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological sex steroid replacement (pSSR)
Number of subjects: 34
Study 22343553 — intervention group
Group type: COMPARATOR
Intervention: Standard sex steroid replacement (sSSR)
Number of subjects: 34
Study 20199783 — intervention group
Group type: EXPERIMENTAL
Intervention: External limb compression at 100 mm Hg (EC100)
Number of subjects: 0
Study 20199783 — intervention group
Group type: EXPERIMENTAL
Intervention: External limb compression at 160 mm Hg (EC160)
Number of subjects: 0
Study 20199783 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance exercise (no external compression)
Number of subjects: 0
Study 20199783 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (70% of 1-repetition maximum)
Number of subjects: 0
Study 19087716 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN + glutamine and arginine (enteral immunonutrition group), n = 14
Number of subjects: 32
Study 19087716 — intervention group
Group type: COMPARATOR
Intervention: EEN group, n = 18
Number of subjects: 32
Study 19087716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EEN and enteral immunonutrition)
Number of subjects: 32
Study 17112304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20mg once daily
Number of subjects: 0
Study 17112304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12966301 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty
Number of subjects: 115
Study 12966301 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 115
Study 10785528 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for nurses
Number of subjects: 0
Study 10785528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 8862940 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg
Number of subjects: 141
Study 8862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg/triamterene 50 mg combination treatment
Number of subjects: 141
Study 1736500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diethylstilbestrol (DES) 1 mg daily
Number of subjects: 26
Study 1736500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6225627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent benzoyl peroxide acetone gel for four weeks
Number of subjects: 0
Study 6225627 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent benzoyl peroxide acetone gel for an additional four weeks
Number of subjects: 0
Study 6225627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acetone gel vehicle)
Number of subjects: 0
Study 6225627 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide acetone gel
Number of subjects: 0
Study 30131297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled vancomycin
Number of subjects: 29
Study 30131297 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 29
Study 29712666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (100,000 IU or 12,000 IU, n = 31 each) administered once monthly for 2 years
Number of subjects: 62
Study 29712666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (standard dose 12,000 IU) administered once monthly for 2 years
Number of subjects: 62
Study 27271717 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cement reinforcing antibacterial implant
Number of subjects: 60
Study 27271717 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study 25212457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral training program for children with FAP (n = 56)
Number of subjects: 112
Study 25212457 — intervention group
Group type: COMPARATOR
Intervention: Active control group focusing on age-appropriate information delivery (n = 56)
Number of subjects: 112
Study 22287058 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Loc™ 180 Wound Closure Device
Number of subjects: 2
Study 22287058 — intervention group
Group type: COMPARATOR
Intervention: Quill™ PDO Knotless Tissue‐Closure Device
Number of subjects: 2
Study 21504972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Lactobacillus casei DN-114 001 (verum)
Number of subjects: 1000
Study 17398307 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg intravenously, started 12 hours before extubation and every 4 hours until tube removal
Number of subjects: 698
Study 17398307 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg intravenously
Number of subjects: 698
Study 17398307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 698
Study 16142596 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg administered at night
Number of subjects: 121
Study 16142596 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at night
Number of subjects: 121
Study 12142389 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 566
Study 12142389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (fadrozole)
Number of subjects: 566
Study 12142389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum HER-2/neu
Number of subjects: 566
Study 12142389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum CA 15-3
Number of subjects: 566
Study 9925695 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable forceps
Number of subjects: 55
Study 9925695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alligator-shaped forceps
Number of subjects: 55
Study 9925695 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a needle within the cup
Number of subjects: 55
Study 9925695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oval-shaped forceps
Number of subjects: 55
Study 9925695 — intervention group
Group type: COMPARATOR
Intervention: Individual biopsy forceps
Number of subjects: 55
Study 7738458 — intervention group
Group type: COMPARATOR
Intervention: Standard double-blind study
Number of subjects: 0
Study 7738458 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 2288051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg orally, twice a day for 4 days
Number of subjects: 61
Study 2288051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally, twice a day for 4 days
Number of subjects: 61
Study 7293935 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid preparation
Number of subjects: 8
Study 7293935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31971899 — intervention group
Group type: EXPERIMENTAL
Intervention: VASCADE MVP Venous Vascular Closure System (VVCS)
Number of subjects: 204
Study 31971899 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 204
Study 30929415 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29967411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40
Study 29967411 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (inactive treatment)
Number of subjects: 40
Study 26573431 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 80
Study 26573431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24928802 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-releasing suppository
Number of subjects: 323
Study 24928802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 23210068 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg
Number of subjects: 66
Study 23210068 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-dexamethasone (0.075 mg/kg + 0.05 mg/kg)
Number of subjects: 66
Study 23210068 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-dexamethasone
Number of subjects: 66
Study 23210068 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 66
Study 19279077 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary protein (20% energy)
Number of subjects: 27
Study 19279077 — intervention group
Group type: COMPARATOR
Intervention: Low dietary protein (10% energy)
Number of subjects: 27
Study 17618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 80
Study 17618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Allium sativum
Number of subjects: 80
Study 17618098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15126745 — intervention group
Group type: EXPERIMENTAL
Intervention: PET placement
Number of subjects: 63
Study 15126745 — intervention group
Group type: EXPERIMENTAL
Intervention: PET placement and adenoidectomy
Number of subjects: 63
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR2
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*0501
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*0601
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DR2
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DR2, DQB1*0501, DQB1*0601
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*0503
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*0201 and DPB1*0901
Number of subjects: 56
Study 11590899 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1*0601 and DQB1*0503 and *0301
Number of subjects: 56
Study 9713301 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 150
Study 7889885 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation (2.5 mg for 7 weeks)
Number of subjects: 19
Study 7889885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7889885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Boron and Placebo)
Number of subjects: 19
Study 3300457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 240 mg twice a day)
Number of subjects: 196
Study 3300457 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 to 180 mg twice a day)
Number of subjects: 196
Study 3300457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with Hydrochlorothiazide (for patients not achieving treatment goal)
Number of subjects: 196
Study 3300457 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 196
Study 3300457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 196
Study 29529656 — intervention group
Group type: EXPERIMENTAL
Intervention: XLPE liners
Number of subjects: 220
Study 29529656 — intervention group
Group type: COMPARATOR
Intervention: CPE liners
Number of subjects: 220
Study 28974165 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-training intervention (Pay Attention!)
Number of subjects: 15
Study 28974165 — intervention group
Group type: COMPARATOR
Intervention: Play control group
Number of subjects: 15
Study 28974165 — intervention group
Group type: COMPARATOR
Intervention: Test-only control group
Number of subjects: 15
Study 26537941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 537
Study 26537941 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals (zidovudine/lamivudine and nelfinavir or lopinavir/ritonavir)
Number of subjects: 537
Study 26537941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) with antiretrovirals
Number of subjects: 537
Study 26537941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 537
Study 23535340 — intervention group
Group type: EXPERIMENTAL
Intervention: MISC caregiver training program
Number of subjects: 119
Study 23535340 — intervention group
Group type: COMPARATOR
Intervention: Health and nutrition curriculum (Control)
Number of subjects: 119
Study 22017782 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 275 mg every 12 hours for 120 hours
Number of subjects: 161
Study 22017782 — intervention group
Group type: COMPARATOR
Intervention: Placebo 275 mg every 12 hours for 120 hours
Number of subjects: 161
Study 17634178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual 24% sucrose (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Number of subjects: 20
Study 17634178 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (0.5-2 ml varying with body weight) administered 2 min before nasogastric tube insertion
Number of subjects: 20
Study 17634178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual 24% sucrose
Number of subjects: 20
Study 17634178 — intervention group
Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 20
Study 12871445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU anti-factor Xa, first dose 6 h after surgery)
Number of subjects: 381
Study 12871445 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg, first dose 12 h before surgery)
Number of subjects: 381
Study 12871445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 381
Study 12871445 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 381
Study 12871445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 381
Study 10594526 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg
Number of subjects: 8
Study 10594526 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5.0 mg
Number of subjects: 8
Study 10594526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7849309 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemic cells causing histopathologically detectable leukemia in SCID mice
Number of subjects: 42
Study 7849309 — intervention group
Group type: COMPARATOR
Intervention: Leukemic cells not causing histopathologically detectable leukemia in SCID mice
Number of subjects: 42
Study 2352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 0
Study 2352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 7/7/7
Number of subjects: 0
Study 2352250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Novum 1/35
Number of subjects: 0
Study 392853 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine monohydrochloride, 1,000 mg daily for five days
Number of subjects: 104
Study 392853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 31597523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic overexpression of miR-149 by transfecting miR-149 mimics
Number of subjects: 0
Study 31597523 — intervention group
Group type: COMPARATOR
Intervention: CircRNA-HIPK3
Number of subjects: 0
Study 30496612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging for 28 days
Number of subjects: 5
Study 30496612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging time
Number of subjects: 5
Study 28877404 — intervention group
Group type: EXPERIMENTAL
Intervention: PWB training (six-session intervention)
Number of subjects: 32
Study 28877404 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 32
Study 25822924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketamine (2 mg/kg)
Number of subjects: 60
Study 25822924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized dexmedetomidine (2 μg/kg)
Number of subjects: 60
Study 25822924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nebulized dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)
Number of subjects: 60
Study 23818535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (information leaflet, two telephone calls, letters over 12 months)
Number of subjects: 66
Study 23818535 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment alone (Control)
Number of subjects: 66
Study 21114602 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Oral-lyn puffs (1 puff = 1 s.c. rapid insulin UI), split into two doses before and after OGTT
Number of subjects: 31
Study 21114602 — intervention group
Group type: COMPARATOR
Intervention: 6 Oral-lyn puffs (used in group C)
Number of subjects: 31
Study 19182178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 19182178 — intervention group
Group type: COMPARATOR
Intervention: Social activity therapy (SAT)
Number of subjects: 0
Study 17483968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel for 4 months
Number of subjects: 20
Study 17483968 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 20
Study 17483968 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin after placebo for 4 months
Number of subjects: 20
Study 17483968 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical analysis
Number of subjects: 20
Study 15464315 — intervention group
Group type: EXPERIMENTAL
Intervention: QuaDDS stents (13- and 17-mm)
Number of subjects: 266
Study 15464315 — intervention group
Group type: COMPARATOR
Intervention: Control stents (uncoated)
Number of subjects: 266
Study 11448318 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy for choroidal melanoma
Number of subjects: 8712
Study 11448318 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients who enrolled
Number of subjects: 8712
Study 11448318 — intervention group
Group type: COMPARATOR
Intervention: Eligible patients not enrolled
Number of subjects: 8712
Study 11448318 — intervention group
Group type: COMPARATOR
Intervention: Ineligible patients
Number of subjects: 8712
Study 11448318 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled patients
Number of subjects: 8712
Study 9579836 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC+G‐CSF (n = 11)
Number of subjects: 23
Study 9579836 — intervention group
Group type: COMPARATOR
Intervention: PBPC alone (n = 12)
Number of subjects: 23
Study 8043974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kgBW daily for 1 week, then tapered by 0.1 mg/kg BW/week for 1 month) and chlorambucil (0.12 mg/kgBW daily) administered during months 1-6.
Number of subjects: 17
Study 8043974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone and chlorambucil therapy
Number of subjects: 17
Study 3052785 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP) alone (total dose, 6 mg/kg)
Number of subjects: 50
Study 3052785 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) plus Dexamethasone (DMS) (total dose, 60 mg)
Number of subjects: 50
Study 30500309 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weekly cellphone-delivered sessions of stigma and alcohol-enhanced behavioural self-regulation counselling
Number of subjects: 50